Combination of Afinitor, exemestane reduces risk of breast cancer progression in wome

[News]

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

More... (http://www.news-medical.net/news/20110926/Combination-of-Afinitor-exemestane-reduces-risk-of-breast-cancer-progression-in-women.aspx)